一季度新签订单同比增长超过30%
The company said Q1 new orders grew over 30% YoY, with small-molecule CDMO orders up over 50%.
Possible impact:May affect views on future revenue recognition and CDMO demand momentum.
康龙化成View source
기업 프로필 · Healthcare
Pharmaron Beijing Co Ltd
300759 · 선전
기타 상장3759 · 홍콩
- 거래소
- 선전
- 국가 / 지역
- China
- 직원 수
- 25,088
현재가
¥38.77
실시간 · 2026년 7월 27일
적정 매수가
≤ ¥25
안전마진 진입가
베일리 성장 점수
55/100
보통
내재가치 · 3단계 구간
현재가 ¥38.77 실시간 · 적정 구간과 낙관적 구간 사이
현재가 ¥38.77
종합 밸류에이션 구간 · 보수적 ¥22–¥25 / 적정 ¥28–¥35 / 낙관적 ¥41–¥47. ¥38.77 기준, 적정 구간과 낙관적 구간 사이.
보고서 발행 시 ¥29.11（2026년 7월 3일）
Recent developments
康龙化成披露2026年一季度业绩
Q1 2026 revenue rose 15.48% to RMB3.58bn; attributable net profit rose 9.75% to RMB335m.
Possible impact:May affect expectations for full-year growth, margin resilience and order conversion.
康龙化成View source
制剂CDMO签订国际大型药企战略合作
Pharmaron said its Beijing formulation commercial facility was completed and signed a GLP-1 manufacturing partnership with a major global pharma.
Possible impact:May affect expectations for formulation CDMO commercialization capability and customer quality.
康龙化成View source
康龙化成发布2025年年度报告
2025 revenue rose 14.82% to RMB14.10bn; attributable net profit fell 7.22%, while recurring net profit rose 38.85%.
Possible impact:May affect views on core business recovery, one-off items and earnings quality.
康龙化成View source
康龙化成披露2025年年度报告
Pharmaron released its 2025 annual report covering operations, R&D spending, segment performance and cash flow.
Possible impact:May shape expectations for CRO demand, cost control and medium-term growth quality.
巨潮资讯网View source
Automatically summarized from public sources; for context only, not investment advice.
재무 개요
시가총액CN¥707.91억
매출 (TTM)CN¥145.75억
EBITDACN¥31.12억
순이익률11.62%
ROE9.99%
PER (TTM)40.56
선행 PER32.89
EPSCN¥0.95
배당수익률0.51%
52주 범위CN¥20.87 – CN¥42.00
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
회사 소개
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
기본 정보
연혁
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
업계 내 위치
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
이 종목에 대한 리포트